StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
6-factor scoring with sector-relative rank. Updated daily.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-11 | $3.83 | $3.81 | -0.52% | 0.1M |
| 05-12 | $3.77 | $3.99 | +5.84% | 0.1M |
| 05-13 | $4.01 | $3.91 | -2.49% | 0.1M |
| 05-14 | $3.95 | $3.72 | -5.82% | 0.0M |
| 05-15 | $3.65 | $3.51 | -3.84% | 0.1M |
Earnings (▲ beat / ▼ miss) and ex-dividend dates plotted on the price line. Educational — proximity does not establish causation.
Each factor shows TKNO's percentile within the scored universe — observational ranking, not a recommendation.
Past 1 reported quarters: EPS surprise vs estimate and the day-after-release stock reaction. Past performance does not predict future moves.
Sources: Finnhub earnings calendar + Polygon daily aggregates. Reaction direction can diverge from EPS surprise (guidance, macro, or sector flow can dominate the next-day print).
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
| Metric | Q3 2026 (Est.) Expected 2026-08-03 | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|---|
Revenue | $11.19M | $11.08M | $40.52M | $30.54M | $20.08M |
Operating Income | Not available | $-4.30M | $-16.98M | $-12.37M | $-8.35M |
Net Income | Not available | $-4.55M | $-17.26M | $-12.50M | $-8.21M |
EPS (Diluted) | $-0.08 | $-0.08 | $-0.32 | $-0.23 | $-0.15 |
Total Assets | Not available | $98.66M | $103.58M | $107.63M | $110.49M |
Total Liabilities | Not available | $33.73M | $34.81M | $34.98M | $34.43M |
Cash & Equivalents | Not available | $4.31M | $5.91M | $3.20M | $3.28M |
Free Cash Flow OCF − CapEx | Not available | $-3.58M | $-9.79M | $-8.98M | $-6.62M |
Shares Outstanding | Not available | 53.61M | 53.56M | 53.52M | 53.51M |
No sell-side coverage available for TKNO.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
Alpha Teknova Inc is a producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics. Its offer two primary product categories: Lab Essentials and Clinical Solutions. It derives key revenue from the United States. The company offers three primary product types: (i) pre-poured media plates for cell growth and cloning; (ii) liquid microbial culture media and supplements for cellular expansion; and (iii) molecular biology reagents for sample manipulation, resuspension, and purification.
Fundamentals not available for TKNO.
No fundamental metrics available yet for this ticker — common for ETFs, foreign issuers without US listing depth, very recent IPOs, or thinly-traded OTC names. The Financials tab pulls from SEC EDGAR directly and may still have data.